Developer docs
API playgroundTry for free, no card

Search company profiles

Emerald Medical Applications

Full company profile

uuid0008wni

Namestring
Emerald Medical Applications
Legal namestring
Derma Compare Health Engine
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Emerald Medical Applications was founded in 2010 in Petah Tiqva, Israel, and is associated with the OTCQB ticker MRLA, which source data now indicates is delisted. The company was originally positioned around a population-wide melanoma screening proposition, but no proprietary technology, AI/ML capabilities, clinical validation, regulatory clearances, or product details are disclosed in the source data. Headcount is reported at 1-10 employees and no pricing model, customer segments, or revenue mechanics are documented.

The company's only currently observable operating asset is the Derma Compare Health Engine website (dermacompare.com), which functions as a consumer-facing health information portal. The site publishes articles spanning plastic surgery recovery, blood pressure management, hair transplants, psychedelics therapy, cosmetic dentistry, dental care, infertility, skin diseases, acid reflux, CBD products, cannabis health benefits, contact lens care, anxiety, and breast cancer prevention. Content authorship is attributed to named freelancers (e.g., Maximilian Huff, Victoria Lawson), with publication dates ranging from 2018 through 2025. A Facebook page and Pinterest profile provide supplementary social distribution.

The company's capital history consists of a single disclosed $1,000,000 funding event in May 2016 from Kodiak Capital Group. No management team, board, ownership structure, partnerships, M&A activity, or subsequent capital raises are documented. The disconnect between the original melanoma-screening mission and the current generalist health content operation, combined with delisted status and minimal headcount, signals an entity that has either substantially pivoted, wound down core operations, or maintains only nominal corporate activity.

Short descriptiontext

Emerald Medical Applications (Derma Compare Health Engine) is an Israel-based, now privately held company that operates dermacompare.com, a consumer-facing health information portal publishing articles on diverse medical and wellness topics, with no proprietary technology or revenue model disclosed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPetah Tiqva, Israel
HQ citystring
Petah Tiqva
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
melanoma screening software, dermatology screening platform, skin lesion analysis, health information portal, medical content publishing
Industry2 codes
PRIMARYHLAKACAA
General & Medical Dermatology
SECONDARYHLAKACAC
Dermatopathology
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Health Services8000
Product category
Skin Cancer Screening
Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeSoftware
Software
Core offering1 text field

Emerald Medical Applications positions itself as the first of its kind population-wide melanoma screening offering, marketed through its consumer-facing Derma Compare Health Engine website. The active site publishes general health editorial content across dermatology, plastic surgery recovery, blood pressure, hair transplants, psychedelics, cosmetic dentistry, and related wellness topics rather than a documented screening workflow.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data does not contain information about Emerald Medical Applications. The content primarily covers Derma Compare Health Engine (dermacompare.com), a health information website that publishes articles on various health topics including plastic surgery recovery, blood pressure management, hair transplants, psychedelics therapy, cosmetic dentistry, protein nutrition, dental care, infertility, skin diseases, cosmetic surgery procedures, acid reflux diet, CBD products, cannabis health benefits, cycling, table tennis, sexual health, lip augmentation, contact lens care, anxiety management, and breast cancer prevention.

Product and service2 records
1Derma Compare Health Engine
2Population-Wide Melanoma Screening
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Healthline is a large-scale health information publisher with medically-reviewed dermatology and skin-health sections. It is the closest broad incumbent to what dermacompare.com operates as in practice.

TypeBroad incumbent
Description

Verywell Health publishes medically-reviewed consumer health content across dermatology and adjacent topics, and is a comparable incumbent competing for the same general health-content traffic dermacompare.com targets.

TypeEmerging player
Description

SkinIO provides AI-based total body photography and skin lesion tracking for dermatology clinics and at-risk patients. It competes for the same melanoma/skin-cancer screening workflow that Emerald Medical claims to target, with an emerging commercial footprint.

4DermAssist (Google Health)
TypeBroad incumbent
Description

Google's DermAssist is a web-based AI dermatology triage tool that matches user photos to dermatologic conditions. It represents a major incumbent threat in the dermatology self-screening category where Emerald Medical would compete if it relaunched its screening product.

TypeDirect peer
Description

MoleSafe operates a melanoma surveillance and skin imaging service combining digital dermoscopy with dermatologist review. It is a directly comparable skin-lesion screening service targeting the same population-level melanoma detection use case.

TypeRegional player
Description

DermNet NZ is a well-established dermatology-specific health information resource run by a New Zealand charitable trust. It represents a credible dermatology-focused information site, comparable to what Emerald Medical would need to become to differentiate.

TypeDirect peer
Description

SkinVision offers an AI-driven smartphone app for skin lesion and melanoma risk assessment, directly comparable to the population-wide melanoma screening ambition stated by Emerald Medical Applications. Both target early melanoma/skin cancer detection via consumer-accessible technology.

TypeEmerging player
Description

First Derm offers on-demand dermatology triage via photo-based online consultations. It overlaps with Emerald Medical's stated melanoma screening goal by combining self-screening with dermatologist review in a consumer-accessible format.

9MoleMapper
TypeEmerging player
Description

MoleMapper is a research-grade iPhone app developed with OHSU that helps users track and document moles over time for melanoma monitoring. It is an emerging, partially-overlapping peer for skin self-screening functionality.

TypeBroad incumbent
Description

WebMD is a dominant consumer health information portal covering dermatology, oncology, and general wellness topics. As a broad incumbent, it competes for the same health-information/SEO audience that dermacompare.com actually serves today.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Emerald Medical Applications

Skin Cancer Screeningdermacompare.com

Emerald Medical Applications (Derma Compare Health Engine) is an Israel-based, now privately held company that operates dermacompare.com, a consumer-facing health information portal publishing articles on diverse medical and wellness topics, with no proprietary technology or revenue model disclosed.

What Emerald Medical Applications does

Emerald Medical Applications was founded in 2010 in Petah Tiqva, Israel, and is associated with the OTCQB ticker MRLA, which source data now indicates is delisted. The company was originally positioned around a population-wide melanoma screening proposition, but no proprietary technology, AI/ML capabilities, clinical validation, regulatory clearances, or product details are disclosed in the source data. Headcount is reported at 1-10 employees and no pricing model, customer segments, or revenue mechanics are documented.

The company's only currently observable operating asset is the Derma Compare Health Engine website (dermacompare.com), which functions as a consumer-facing health information portal. The site publishes articles spanning plastic surgery recovery, blood pressure management, hair transplants, psychedelics therapy, cosmetic dentistry, dental care, infertility, skin diseases, acid reflux, CBD products, cannabis health benefits, contact lens care, anxiety, and breast cancer prevention. Content authorship is attributed to named freelancers (e.g., Maximilian Huff, Victoria Lawson), with publication dates ranging from 2018 through 2025. A Facebook page and Pinterest profile provide supplementary social distribution.

The company's capital history consists of a single disclosed $1,000,000 funding event in May 2016 from Kodiak Capital Group. No management team, board, ownership structure, partnerships, M&A activity, or subsequent capital raises are documented. The disconnect between the original melanoma-screening mission and the current generalist health content operation, combined with delisted status and minimal headcount, signals an entity that has either substantially pivoted, wound down core operations, or maintains only nominal corporate activity.

Emerald Medical Applications firmographics

Firmographics
Name
Emerald Medical Applications
Legal name
Derma Compare Health Engine
Website
https://dermacompare.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Emerald Medical Applications (Derma Compare Health Engine) is an Israel-based, now privately held company that operates dermacompare.com, a consumer-facing health information portal publishing articles on diverse medical and wellness topics, with no proprietary technology or revenue model disclosed.
Ownership category
akta.pro rank

Emerald Medical Applications industry classification

Industry
Product category
Skin Cancer Screening
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAKACAA
General & Medical Dermatology
SECONDARYHLAKACAC
Dermatopathology

Keywords

  • Melanoma screening software
  • Dermatology screening platform
  • Skin lesion analysis
  • Health information portal
  • Medical content publishing

Where Emerald Medical Applications is headquartered

Location

Headquarters

HQ city
Petah Tiqva
HQ country
Israel
HQ region
Middle East

Markets served

Emerald Medical Applications business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Emerald Medical Applications product offering

Product offering

Core offering

Emerald Medical Applications positions itself as the first of its kind population-wide melanoma screening offering, marketed through its consumer-facing Derma Compare Health Engine website. The active site publishes general health editorial content across dermatology, plastic surgery recovery, blood pressure, hair transplants, psychedelics, cosmetic dentistry, and related wellness topics rather than a documented screening workflow.

Product overview

The source data does not contain information about Emerald Medical Applications. The content primarily covers Derma Compare Health Engine (dermacompare.com), a health information website that publishes articles on various health topics including plastic surgery recovery, blood pressure management, hair transplants, psychedelics therapy, cosmetic dentistry, protein nutrition, dental care, infertility, skin diseases, cosmetic surgery procedures, acid reflux diet, CBD products, cannabis health benefits, cycling, table tennis, sexual health, lip augmentation, contact lens care, anxiety management, and breast cancer prevention.

Differentiator

Problem solved

Functional benefit

Products and services

  • Derma Compare Health Engine
  • Population-Wide Melanoma Screening

Companies that use Emerald Medical Applications

Customer profile

Ideal customer profiles1 record

Emerald Medical Applications technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Emerald Medical Applications partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Emerald Medical Applications competitors and assessment

Company assessment

Broad incumbents

  • Healthline: Healthline is a large-scale health information publisher with medically-reviewed dermatology and skin-health sections. It is the closest broad incumbent to what dermacompare.com operates as in practice.
  • Verywell Health: Verywell Health publishes medically-reviewed consumer health content across dermatology and adjacent topics, and is a comparable incumbent competing for the same general health-content traffic dermacompare.com targets.
  • DermAssist (Google Health): Google's DermAssist is a web-based AI dermatology triage tool that matches user photos to dermatologic conditions. It represents a major incumbent threat in the dermatology self-screening category where Emerald Medical would compete if it relaunched its screening product.
  • WebMD: WebMD is a dominant consumer health information portal covering dermatology, oncology, and general wellness topics. As a broad incumbent, it competes for the same health-information/SEO audience that dermacompare.com actually serves today.

Emerging players

  • SkinIO: SkinIO provides AI-based total body photography and skin lesion tracking for dermatology clinics and at-risk patients. It competes for the same melanoma/skin-cancer screening workflow that Emerald Medical claims to target, with an emerging commercial footprint.
  • First Derm: First Derm offers on-demand dermatology triage via photo-based online consultations. It overlaps with Emerald Medical's stated melanoma screening goal by combining self-screening with dermatologist review in a consumer-accessible format.
  • MoleMapper: MoleMapper is a research-grade iPhone app developed with OHSU that helps users track and document moles over time for melanoma monitoring. It is an emerging, partially-overlapping peer for skin self-screening functionality.

Direct peers

  • MoleSafe: MoleSafe operates a melanoma surveillance and skin imaging service combining digital dermoscopy with dermatologist review. It is a directly comparable skin-lesion screening service targeting the same population-level melanoma detection use case.
  • SkinVision: SkinVision offers an AI-driven smartphone app for skin lesion and melanoma risk assessment, directly comparable to the population-wide melanoma screening ambition stated by Emerald Medical Applications. Both target early melanoma/skin cancer detection via consumer-accessible technology.

Regional players

  • DermNet NZ: DermNet NZ is a well-established dermatology-specific health information resource run by a New Zealand charitable trust. It represents a credible dermatology-focused information site, comparable to what Emerald Medical would need to become to differentiate.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

Emerald Medical Applications social profiles

Digital presence

Emerald Medical Applications financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Emerald Medical Applications leadership team

Management profile

Number of profiles

Emerald Medical Applications funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Emerald Medical Applications M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emerald Medical Applications

What does Emerald Medical Applications do?

Emerald Medical Applications positions itself as the first of its kind population-wide melanoma screening offering, marketed through its consumer-facing Derma Compare Health Engine website. The active site publishes general health editorial content across dermatology, plastic surgery recovery, blood pressure, hair transplants, psychedelics, cosmetic dentistry, and related wellness topics rather than a documented screening workflow.

Is Emerald Medical Applications a public or private company?

Emerald Medical Applications is a private company. It is classified as unknown and is currently operating.

When was Emerald Medical Applications founded?

Emerald Medical Applications was founded in 2010. It employs 1 to 10 people.

Where is Emerald Medical Applications based?

Emerald Medical Applications is headquartered in Petah Tiqva, Israel, in the Middle East region.

Who are Emerald Medical Applications's main competitors?

Broad incumbents on record are Healthline, Verywell Health, DermAssist (Google Health) and WebMD. Emerging players are SkinIO, First Derm and MoleMapper. Direct peers are MoleSafe and SkinVision. DermNet NZ is listed as a regional player.

Does Emerald Medical Applications have an API?

No public API is recorded for Emerald Medical Applications.

What industry is Emerald Medical Applications in?

Emerald Medical Applications's product category is Skin Cancer Screening. Its primary akta.pro industry code is HLAKACAA, General & Medical Dermatology, with a secondary code of HLAKACAC, Dermatopathology. Its NAICS code is 62151 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEmerald Medical Applications Announces Closing of Stock Purchase Agreement With Publicis Groupe at $0.40 per SharePublicis Groupe completed the purchase of 1,315,563 shares of Emerald Medical Applications Corp. common stock for a total investment of $526,225.20 at $0.40 per share. The investment resulted from Emerald winning the Grand Prize at Publicis Groupe's "Publicis 90" Initiative at the Viva Technology event held in Paris, France in July 2016. Emerald's CEO stated the capital and mentoring from Publicis will help commercialize their DermaCompare skin cancer screening platform.PR NewswireEmerald Medical Applications Enters Joint Sponsorship Agreement with the Hispanic Professionals Association Inc. NYEmerald Medical Applications Corp. signed a term sheet with the Hispanic Professionals Association Inc. New York (AHPSI) to sponsor the marketing of its DermaCompare skin cancer detection technology to AHPSI's physician and nurse members. AHPSI is a professional society serving Hispanic medical professionals through 12 annual Community Health Fairs and over 30 mini-conferences in the Mid Atlantic region. The company's CEO expects this partnership to drive thousands of patient app downloads and increase awareness for early melanoma detection.PR NewswireEmerald Medical Applications Corp. to Present at the 2016 Marcum MicroCap Conference on June 2, 2016 in New York CityEmerald Medical Applications Corp. announced it will present at the 2016 Marcum MicroCap Conference at the Grand Hyatt New York on June 1-2, 2016, with CFO Consultant Joseph Salvani providing an overview of the company's vision, products, and growth strategy.PR NewswireEmerald Medical Applications Corp. Announces $1 Million Equity Purchase Agreement with Kodiak Capital Group, LLCEmerald Medical Applications Corp. entered into a $1 million equity purchase agreement with Kodiak Capital Group, LLC, giving Emerald the right to sell common stock to the private investment fund. Proceeds from the financing will be used as working capital to promote the company's DermaCompare melanoma detection technology in the United States. Kodiak's Managing Member cited belief in artificial intelligence as a key factor in the investment, expressing confidence in AI applications as the fastest growing commercial technology sector.PR NewswireEmerald Medical Applications Corp (OTCQB: MRLA) Appoints Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to its Scientific Advisory BoardEmerald Medical Applications Corp announced the appointment of Dr. Ben-Zion Weiner to its Scientific Advisory Board on May 18, 2016. Dr. Weiner previously served as Vice President of Global Products at Teva Pharmaceutical Industries from 2005 to 2011, where he oversaw global Generic and Innovative R&D. The company stated that his expertise in chemistry, pharmacology, and pharmaceutical products will help maximize the potential of its DermaCompare™ AI-powered skin cancer detection technology.PR NewswireDr. Perry Robins, Mohs Surgery Pioneer, Joins Emerald Medical ApplicationsEmerald Medical Applications Corp. announced that Dr. Perry Robins, a pioneer in Mohs surgery and founder of The Skin Cancer Foundation, has joined its Medical Advisory Board. This appointment aims to leverage Dr. Robins' expertise to support the commercialization of the company's DermaCompare™ AI technology for skin cancer diagnosis.PR NewswireEmerald Medical Applications Corp. to Present at the Joseph Gunnar & Co. PIONEERS 2016 Conference on May 5, 2016 in New York CityEmerald Medical Applications Corp. will present at the Joseph Gunnar & Co. PIONEERS 2016 Conference on May 5, 2016 in New York City, with Chief Financial Consultant Joseph Salvani providing an overview of the company's vision, product, and growth strategy. The Israeli-based medical technology company, which develops the DermaCompare™ AI-powered skin cancer detection platform, recently won third prize out of 25 competing tech companies at the Innovation Competition Of International Talents in Shenzhen, selected from 1,500 entries across five preliminary competitions. The company is using the conference appearance to engage with the investment community and schedule one-on-one meetings.PR NewswireEmerald Medical Applications Wins Third Prize at the Innovation Competition Of International Talents in Shenzen, ChinaEmerald Medical Applications Corp., an Israeli medical technology company, was awarded third prize out of 25 competing tech companies at the Innovation Competition of International Talents held in Shenzhen, China, recognizing its DermaCompare AI platform for early melanoma and skin cancer detection. The company qualified for the finals by finishing second among 300 Israeli entrants at a preliminary competition hosted by SOSA Incubator in Tel Aviv. CEO Lior Wayn stated the company plans to work with SETO to introduce DermaCompare to the Chinese market and broader Asia region.PR NewswireEmerald Medical Applications’ DermaCompare™ Chosen Israeli Technology Most Likely to Succeed in BrazilEmerald Medical Applications Corp., an Israeli medical technology company, announced that its DermaCompare™ AI skin cancer detection platform was selected by the Israel-Brazil Chamber of Commerce as the Israeli technology most likely to succeed in Brazil. The company simultaneously entered an exclusive three-year distribution agreement with Laser Brazil Technology (LBT) for sales throughout Brazil, with a minimum revenue requirement of $7 million to maintain exclusivity. DermaCompare enables patients to conduct self dermatology scans using total body photography imaging via smartphone or tablet, with the platform targeting Brazil's rising melanoma incidence rates.PR NewswireEmerald Announces Implementation of its Cloud Based, Artificial Intelligence, DermaCompare™ Technology With TEREM, one of the Largest Israeli Medical ClinicsEmerald Medical Applications Corp. announced a cooperation agreement with Terem to deploy its DermaCompare™ cloud-based artificial intelligence skin cancer detection technology across Terem's 17 medical clinics throughout Israel starting April 2016. The FDA-approved, HIPAA-compliant technology uses total body photography imaging that automatically compares current images with prior scans to detect melanoma in its earliest stages. Emerald expects the partnership to generate significant revenues starting in the second half of 2016.